Last updated: August 2, 2026
TAUVID, Eli Lilly’s flortaucipir F 18 injection, is a specialized diagnostic PET agent approved in 2020 to estimate the density and distribution of aggregated tau neurofibrillary tangles in adults being evaluated for Alzheimer’s disease. Its commercial opportunity is limited by PET infrastructure, radiopharmaceutical logistics, reimbursement, and the absence of a direct disease-modifying treatment decision tied to tau imaging. Lilly does not report TAUVID revenue as a standalone product, so its financial contribution is not publicly quantifiable. The product’s strategic value is greater as an Alzheimer’s diagnostic platform and clinical-development tool than as a major revenue driver.
What is TAUVID and what is its FDA-approved use?
TAUVID is the brand name for flortaucipir F 18 injection, a radioactive diagnostic agent administered intravenously before PET imaging. The FDA approved TAUVID on May 28, 2020, under New Drug Application 212123. The product is indicated for brain imaging to estimate the density and distribution of aggregated tau neurofibrillary tangles in adults being evaluated for Alzheimer’s disease [1].
TAUVID is not approved to:
- Diagnose Alzheimer’s disease by itself
- Predict future cognitive decline
- Monitor treatment response
- Select patients for an approved Alzheimer’s disease therapy
- Replace clinical, cognitive, genetic, or structural-imaging assessments
The label states that a positive scan indicates the presence of aggregated tau consistent with Alzheimer’s disease pathology. A negative scan indicates sparse to no aggregated tau pathology but does not exclude early disease or other causes of cognitive impairment [1].
TAUVID product profile
| Attribute |
TAUVID status |
| Active ingredient |
Flortaucipir F 18 |
| Manufacturer |
Eli Lilly and Company |
| FDA application |
NDA 212123 |
| FDA approval |
May 28, 2020 |
| Dosage form |
Intravenous injection for PET imaging |
| Clinical use |
Estimation of aggregated tau neurofibrillary tangles |
| Disease area |
Alzheimer’s disease evaluation |
| Product type |
Diagnostic radiopharmaceutical |
| Therapeutic effect |
None |
| Administration |
Single intravenous PET-tracer dose |
| Radioisotope |
Fluorine-18 |
| Physical half-life |
Approximately 110 minutes |
| Revenue disclosure |
Not separately reported by Lilly |
How large is the TAUVID market?
The addressable market is narrower than the overall Alzheimer’s diagnostics market. TAUVID requires PET imaging capacity, a nuclear pharmacy or cyclotron supply chain, trained readers, referral from a cognitive-disorders specialist, and reimbursement for a tau-specific scan.
The commercial market has several layers:
- Patients undergoing evaluation for Alzheimer’s disease.
- Patients for whom tau burden would change diagnostic confidence or staging.
- Health systems with access to PET equipment and radiopharmaceutical distribution.
- Payers willing to reimburse tau PET imaging.
- Clinical-trial sponsors using tau imaging as a biomarker.
The largest near-term commercial limitation is reimbursement. Amyloid PET has a more established role in determining whether patients may be eligible for anti-amyloid therapies such as lecanemab and donanemab. Tau PET is clinically relevant, but it has not occupied the same central position in treatment eligibility decisions.
The launch of disease-modifying Alzheimer’s therapies creates an indirect opportunity for TAUVID. As treatment pathways become more complex, physicians may seek additional information on disease stage and pathology. The commercial effect remains constrained because current treatment-selection pathways generally depend on amyloid confirmation, not tau PET alone.
What is the financial trajectory of TAUVID?
Lilly does not disclose TAUVID net sales, gross margin, prescription volume, or operating profit separately in its annual reports. The product is therefore best classified as a non-material or undisclosed contributor within Lilly’s broader portfolio rather than as a separately tracked growth franchise [2].
Revenue trajectory
| Period |
Financial status |
| 2020 |
FDA approval and commercial launch |
| 2021-2022 |
Early commercialization affected by COVID-19 recovery, PET access, and limited reimbursement |
| 2023 |
Strategic relevance increased with Alzheimer’s disease treatment development, but no standalone revenue disclosure |
| 2024 onward |
Potential demand support from broader Alzheimer’s diagnostic pathways; product-level financial outcome remains undisclosed |
TAUVID has a different financial profile from a conventional pharmaceutical product:
- It is administered once per imaging episode rather than chronically.
- Its revenue depends on scan volume, not daily prescription persistence.
- It requires time-sensitive production and distribution.
- It is vulnerable to PET-center capacity and reimbursement decisions.
- It has limited direct consumer or retail exposure.
- Its commercial value may include clinical-trial and drug-development use that is not reflected in product sales.
Lilly’s major Alzheimer’s revenue opportunity is concentrated in disease-modifying therapies, including donanemab, rather than TAUVID. The diagnostic product can support disease characterization, but it is unlikely to become a major contributor to Lilly’s consolidated revenue without broader reimbursement and routine integration into Alzheimer’s care.
What competitive products challenge TAUVID?
TAUVID competes with other diagnostic methods rather than with a single identical product.
Direct and indirect competitors
| Competitor or alternative |
Target or function |
Commercial position |
| Amyvid |
Amyloid plaque imaging |
FDA-approved amyloid PET agent marketed by Lilly |
| Vizamyl |
Amyloid plaque imaging |
FDA-approved amyloid PET agent |
| Neuraceq |
Amyloid plaque imaging |
FDA-approved amyloid PET agent |
| Cerebrospinal-fluid biomarkers |
Amyloid and tau biomarkers |
Increasing clinical use; invasive but potentially lower cost |
| Plasma biomarkers |
Blood-based amyloid and tau markers |
Rapidly developing; may reduce demand for some PET studies |
| FDG PET |
Brain glucose metabolism |
Established imaging tool but not tau-specific |
| MRI |
Structural brain assessment |
Widely available and routinely used |
| Neuropsychological testing |
Cognitive assessment |
Core component of clinical diagnosis |
| Research tau tracers |
Tau imaging |
Potential future competition, subject to validation and approval |
Amyloid PET is the most important commercial comparator. Amyloid imaging answers whether amyloid pathology is present, which is increasingly relevant to treatment eligibility. TAUVID answers a different question: how much aggregated tau pathology is present and where it is distributed.
Blood-based biomarkers pose a longer-term substitution risk. If validated plasma assays achieve broad regulatory acceptance and payer coverage, they may reduce the number of patients referred for PET imaging. PET would likely retain a role in ambiguous cases, clinical trials, and situations requiring greater spatial information.
What patents protect TAUVID?
TAUVID’s protection is likely based on a combination of patents, regulatory exclusivity, proprietary manufacturing and quality controls, radiopharmaceutical production networks, and know-how. The economic value of patents is less straightforward than for a conventional small-molecule medicine because the product contains a short-lived isotope and must be manufactured close to the imaging site.
A public patent analysis should distinguish among:
- Flortaucipir chemical composition patents
- Radiolabeled compound patents
- Methods of detecting or staging tau pathology
- Formulation and injectable-composition patents
- Manufacturing and radiolabeling processes
- PET imaging interpretation methods
- Clinical-use patents
- Proprietary software or image-analysis tools
No publicly reported patent number, expiration date, Orange Book listing, Paragraph IV challenge, or patent settlement is established here as a controlling commercial fact. The FDA Orange Book should be reviewed against NDA 212123 for current listed patents and regulatory exclusivity information [3]. Patent scope may also exist outside the Orange Book, particularly for diagnostic methods, manufacturing processes, and imaging interpretation.
Are formulation patents important for TAUVID?
Formulation patents are less likely to be the principal long-term barrier than they are for an oral drug. TAUVID is an injectable radiopharmaceutical with a short radioactive half-life. Commercial differentiation depends heavily on:
- Radiochemical purity
- Sterility and endotoxin control
- Batch release
- Stability during shipment
- Accurate activity calibration
- Local production timing
- Distribution radius
- PET-site operating procedures
These factors can deter entry even where patent protection is limited. A competitor would need to reproduce the full manufacturing and distribution system, not merely synthesize a non-radioactive active ingredient.
When does TAUVID lose exclusivity?
TAUVID’s regulatory exclusivity and patent position should be analyzed separately.
The FDA approval date was May 28, 2020. New chemical entity exclusivity, if applicable, generally provides five years from approval, subject to the statutory framework and any patent-certification consequences. That period would ordinarily have run to May 2025, but the exact regulatory status depends on FDA listing and application-specific determinations [4].
A product-specific patent expiry cannot be stated reliably without a verified patent-family review. Radiopharmaceutical products can have multiple relevant patent families, and an Orange Book entry may not capture all commercially relevant rights.
Generic entry risk
Traditional generic substitution risk is limited by the product’s diagnostic and manufacturing characteristics. A competing applicant could potentially use an abbreviated or alternative FDA pathway, but market entry would still require:
- FDA approval of the diagnostic agent
- Demonstration of comparable imaging performance
- Validation of radiochemical manufacturing
- Reliable fluorine-18 supply
- PET-site adoption
- Payer coverage
- Reader training and interpretation standards
A generic or follow-on product would not automatically receive the same clinical adoption as TAUVID. The need for local distribution and physician confidence can preserve commercial friction after formal exclusivity ends.
Has TAUVID faced Paragraph IV challenges or patent litigation?
No widely reported Paragraph IV litigation or major patent settlement involving TAUVID is identified in the cited public sources. The absence of reported litigation is consistent with the product’s limited commercial scale and specialized manufacturing requirements.
The principal legal risks are more likely to involve:
- Patent challenges to flortaucipir chemistry or radiolabeling
- Method-of-use disputes over tau imaging
- Competing diagnostic-tracer patents
- Regulatory exclusivity disputes
- Contractual disputes involving manufacturing or distribution
- Trade-secret protection for production and quality-control methods
The lack of a reported Paragraph IV case does not establish that all patent rights have expired or that entry would be unrestricted. It indicates that no major public challenge is being treated as a current market event in the cited record.
What is the FDA and Orange Book status of TAUVID?
TAUVID is FDA approved as a prescription diagnostic radiopharmaceutical under NDA 212123 [1]. It is not a biologic and does not face biosimilar competition. The relevant regulatory comparison is with other approved PET agents and with potential abbreviated applications for diagnostic radiopharmaceuticals.
The Orange Book is relevant for identifying listed patents and regulatory exclusivity. It is not a complete record of every patent that may affect commercial use. Method-of-use patents, manufacturing patents, and patents held by third parties may be outside the principal Orange Book analysis.
TAUVID’s label contains important safety and interpretation limitations. Image interpretation errors can arise from poor image quality, motion, atypical anatomy, and non-Alzheimer’s tauopathies. These factors increase the importance of trained readers and may slow widespread adoption [1].
What licensing deals support the TAUVID franchise?
TAUVID originated from Avid Radiopharmaceuticals, which Lilly acquired in 2010. The acquisition gave Lilly access to Avid’s molecular imaging portfolio, including amyloid and tau imaging programs [5].
The Avid transaction is the key disclosed strategic deal associated with TAUVID’s commercial lineage. No major later licensing agreement is identified here as a material driver of TAUVID revenue. Lilly’s internal ownership supports control over development, regulatory strategy, manufacturing relationships, and commercialization.
The acquisition also explains why TAUVID and Amyvid sit within the same Lilly diagnostic portfolio. That relationship creates potential commercial efficiencies, but it also places TAUVID alongside a more established amyloid-imaging franchise with clearer relevance to anti-amyloid treatment decisions.
How strong is the TAUVID patent and commercial estate?
TAUVID has a moderate technical and operational barrier but a less clearly dominant commercial position than a protected therapeutic franchise.
Strengths
- FDA approval for a defined tau-imaging use
- Lilly ownership and established Alzheimer’s commercial infrastructure
- Specialized radiolabeling and quality-control requirements
- Need for PET-site implementation and reader training
- Potential use in clinical trials and disease staging
- Limited number of approved tau PET alternatives
Weaknesses
- No standalone revenue disclosure
- Narrow reimbursement base
- Dependence on PET infrastructure
- Potential substitution by plasma biomarkers
- No therapeutic effect
- Amyloid PET has a stronger role in treatment selection
- Product value is sensitive to clinical-guideline adoption
The estate is stronger as an integrated regulatory, manufacturing, and clinical platform than as a simple patent monopoly.
How does TAUVID compare with Amyvid?
| Category |
TAUVID |
Amyvid |
| Active ingredient |
Flortaucipir F 18 |
Florbetapir F 18 |
| Imaging target |
Aggregated tau neurofibrillary tangles |
Amyloid plaques |
| FDA approval |
2020 |
2012 |
| Main clinical role |
Disease staging and tau burden assessment |
Amyloid pathology assessment |
| Relevance to anti-amyloid treatment |
Indirect or complementary |
Directly relevant to confirming amyloid pathology |
| Commercial maturity |
Newer and narrower |
More established |
| Main substitution risk |
Plasma tau and other biomarkers |
Blood-based amyloid biomarkers |
| Lilly relationship |
Lilly-owned |
Lilly-owned |
Amyvid has a stronger near-term commercial position because anti-amyloid treatment pathways require confirmation of amyloid pathology. TAUVID may gain value as treatment expands, but its use is more likely to be complementary than mandatory.
What generic launch scenarios exist for TAUVID?
Three scenarios are commercially plausible.
Scenario 1: Limited entry after regulatory exclusivity
A competitor obtains approval but launches only in selected PET centers. Market share gains remain modest because radiopharmaceutical supply, reimbursement, and reader adoption limit substitution.
Scenario 2: Method or formulation competition
A competitor introduces a different tau tracer with better image characteristics, longer distribution range, easier production, or stronger clinical evidence. This would be a more serious threat than a conventional generic.
Scenario 3: Biomarker substitution
Validated blood-based biomarkers reduce routine PET referrals. TAUVID remains used for complex cases, research, staging, and situations where spatial imaging is clinically valuable.
The highest-risk scenario for TAUVID is not necessarily a generic copy. It is displacement by lower-cost or more convenient biomarkers combined with limited reimbursement for tau PET.
What is the geographic coverage of TAUVID?
TAUVID’s commercial reach depends on the geographic availability of fluorine-18 production and PET imaging centers. The product is most commercially viable in major metropolitan areas, academic hospitals, specialized neurology centers, and clinical-trial networks.
Geographic constraints include:
- Short radioactive half-life
- Limited delivery radius
- Cyclotron and radiopharmacy capacity
- PET scanner availability
- Specialist-reader concentration
- Local payer policy
- National regulatory approval
The United States is the core commercial market based on FDA approval and Lilly’s US commercialization. Broader international revenue would require country-specific approvals, reimbursement, and supply-chain infrastructure. No international approval or revenue contribution is quantified in the cited sources.
Key Takeaways
- TAUVID is an FDA-approved tau PET diagnostic, not a therapeutic Alzheimer’s drug.
- Lilly does not report TAUVID revenue separately, preventing a reliable product-level sales forecast.
- Its commercial opportunity is constrained by PET capacity, reimbursement, and radiopharmaceutical logistics.
- Amyvid has stronger near-term treatment-pathway relevance because amyloid confirmation is central to anti-amyloid therapy use.
- TAUVID’s main strategic value is disease staging, clinical research, and complementary information in Alzheimer’s evaluation.
- Patent and regulatory exclusivity should be reviewed through NDA 212123 and the current Orange Book, but no controlling patent expiry or major Paragraph IV case is established in the cited record.
- The principal long-term threat is substitution by validated blood-based biomarkers or a superior tau tracer, not necessarily a conventional generic.
- TAUVID is unlikely to become a major Lilly revenue contributor without broader reimbursement and routine integration into Alzheimer’s care.
FAQs
Is TAUVID a treatment for Alzheimer’s disease?
No. TAUVID is a diagnostic PET agent used to estimate aggregated tau pathology. It does not slow disease progression or treat Alzheimer’s disease.
Does Medicare cover TAUVID tau PET scans?
Coverage depends on the applicable Medicare policy, claim circumstances, and local contractor rules. Coverage for tau PET has historically been narrower than coverage for some other Alzheimer’s diagnostic services.
Can TAUVID determine whether a patient should receive donanemab?
TAUVID is not the primary test for confirming amyloid pathology required for anti-amyloid treatment decisions. Amyloid PET or another validated amyloid test generally addresses that question.
Is there a biosimilar equivalent to TAUVID?
No. TAUVID is a small-molecule radiopharmaceutical diagnostic, not a biologic. Biosimilar regulation does not apply.
What would most increase TAUVID sales?
The largest commercial catalysts would be broader payer coverage, inclusion in Alzheimer’s diagnostic guidelines, increased PET capacity, use in treatment monitoring or staging protocols, and adoption in clinical trials.
References
- U.S. Food and Drug Administration. (2020). TAUVID (flortaucipir F 18 injection) prescribing information.
- Eli Lilly and Company. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2023). New drug application exclusivity and patent listing resources.
- Eli Lilly and Company. (2010). Lilly completes acquisition of Avid Radiopharmaceuticals.
